NCT06988553 - A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Obesity or OverweightType 2 Diabetes

Interventions

DRUG

AZD5004

AZD5004 will be administered as an oral tablet once daily.

DRUG

Placebo

Placebo will be administered as an oral tablet once daily.

Trial Locations (6)

West China Hospital, Sichuan University, Chengdu

The Fourth Affiliated Hospital of Harbin Medical University, Ha’erbin

The Second People's Hospital of Hefei, Hefei

Jinan Central Hospital, Jinan

Shanghai Pudong New District People's Hospital, Shanghai

General Hospital of Tianjin Medical University, Tianjin